Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor
Open Access
- 15 June 2010
- journal article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 38 (19) , 6567-6576
Abstract
Gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptor superfamily, has been utilized for receptor-mediated targeting of imaging and therapeutic agents; here we extend its use to oligonucleotide delivery. A splice-shifting antisense oligonucleotide was conjugated to a bombesin (BBN) peptide, and its intracellular delivery was tested in GRPR expressing PC3 cells stably transfected with a luciferase gene interrupted by an abnormally spliced intron. The BBN-conjugate produced significantly higher luciferase expression compared to unmodified oligonucleotide, and this increase was reversed by excess BBN peptide. Kinetic studies revealed a combination of saturable, receptor-mediated endocytosis and non-saturable pinocytosis for uptake of the conjugate. The K(m) value for saturable uptake was similar to the EC(50) value for the pharmacological response, indicating that receptor-mediated endocytosis was a primary contributor to the response. Use of pharmacological and molecular inhibitors of endocytosis showed that the conjugate utilized a clathrin-, actin- and dynamin-dependent pathway to enter PC3 cells. The BBN-conjugate partially localized in endomembrane vesicles that were associated with Rab7 or Rab9, demonstrating that it was transported to late endosomes and the trans-golgi network. These observations suggest that the BBN-oligonucleotide conjugate enters cells via a process of GRPR mediated endocytosis followed by trafficking to deep endomembrane compartments.Keywords
This publication has 45 references indexed in Scilit:
- The Biological Effect of an Antisense Oligonucleotide Depends on Its Route of Endocytosis and TraffickingOligonucleotides, 2010
- Rab GTPases as coordinators of vesicle trafficNature Reviews Molecular Cell Biology, 2009
- Biological Barriers to Therapy with Antisense and siRNA OligonucleotidesMolecular Pharmaceutics, 2009
- The promises and pitfalls of RNA-interference-based therapeuticsNature, 2009
- Nonviral Methods for siRNA DeliveryMolecular Pharmaceutics, 2008
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences, 2008
- Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotidesNucleic Acids Research, 2008
- Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosisNucleic Acids Research, 2008
- International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease StatesPharmacological Reviews, 2008
- Chemical modification: the key to clinical application of RNA interference?Journal of Clinical Investigation, 2007